Teva Pharmaceutical Industries Limited Quick Ratio (TEVA) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Teva Pharmaceutical Industries Limited  (NYSE: TEVA)

Teva Pharmaceutical Industries Limited's Quick Ratio

TEVA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Teva Pharmaceutical Industries Limited's Cash & cash equivalent grew by 11.76 % in the Q3 2026 sequentially, while Current Liabilities decreased, this led to improvement in Teva Pharmaceutical Industries Limited's Quick Ratio to 0.26, Quick Ratio remained below Teva Pharmaceutical Industries Limited average.

Within Major Pharmaceutical Preparations industry 413 other companies have achieved higher Quick Ratio than Teva Pharmaceutical Industries Limited in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 3197, from total ranking in the second quarter 2026 at 4022.

Explain Quick Ratio?
How much Cash & cash equivalents TEVA´s has?
What are TEVA´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

TEVA Quick Ratio (Sep 30 2026)
Q3		 (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3
Y / Y Current Liabilities Change 33.96 % 31.68 % 20.96 % -95.47 % -17.83 %
Y / Y Cash & cash equivalent Change 85.43 % 69.13 % 120.45 % 7.76 % -33.62 %
Quick Ratio MRQ 0.26 0.23 0.28 0.25 0.19
TEVA's Total Ranking # 3197 # 4022 # 4064 # 4171 # 4314
Seq. Current Liabilities Change -1.41 % 15.52 % -3.72 % 22.17 % -3.09 %
Seq. Cash & cash equivalent Change 11.76 % -2.3 % 5.2 % 61.42 % 1.94 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 414
Healthcare Sector # 798
Overall Market # 3175


Quick Ratio Statistics
High Average Low
1.59 0.33 0.01
(Dec 31 2015)   (Mar 31 2024)




Financial Statements
Teva Pharmaceutical Industries Limited's Current Liabilities $ 15,425 Millions Visit TEVA's Balance sheet
Teva Pharmaceutical Industries Limited's Cash & cash equivalent $ 4,085 Millions Visit TEVA's Balance sheet
Source of TEVA's Sales Visit TEVA's Sales by Geography


Cumulative Teva Pharmaceutical Industries Limited's Quick Ratio

TEVA's Quick Ratio for the trailling 12 Months

TEVA Quick Ratio

 (Sep 30 2026)
12 Months		 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -83 % -84.25 % -85.37 % -92.53 % 0.18 %
Y / Y Cash & cash equivalent TTM Growth 60.63 % 25.56 % 10.28 % -18.97 % -20.64 %
Quick Ratio TTM 0.26 0.24 0.23 0.2 0.03
Total Ranking TTM # 2728 # 3316 # 2539 # 2536 # 2587
Seq. Current Liabilities TTM Growth 7.14 % 7.38 % 4.82 % -85.9 % -0.72 %
Seq. Cash & cash equivalent TTM Growth 14.31 % 12.81 % 21.25 % 2.73 % -10.65 %

Quick ratio ranking by company, industry and sector >> Back to TEVA Financial Strength Comparisons >> Go to Compare TEVA Quick Ratio to its Competitors

On the trailing twelve months basis TEVA Cash & cash equivalent soared by 85.43 % in Q3 2026 year on year, faster than Current Liabilities, this led to increase in in Teva Pharmaceutical Industries Limited's Quick Ratio to 0.26, above TEVA average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 443 other companies have achieved higher Quick Ratio than Teva Pharmaceutical Industries Limited. While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending second quarter 2026 at 4094.

Explain Quick Ratio?
How much Cash & cash equivalents TEVA´s has?
What are TEVA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 444
Healthcare Sector # 909
Within the Market #


trailing twelve months Quick Ratio Statistics
High Average Low
0.39 0.17 0.05
(Jun 30 2016)  




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Bristol myers Squibb Company  0.67 $ 12,581.000  Millions$ 18,753.000  Millions
Harrow Inc   0.66 $ 75.336  Millions$ 114.224  Millions
Supernus Pharmaceuticals inc   0.62 $ 176.171  Millions$ 285.397  Millions
Axsome Therapeutics Inc   0.62 $ 313.859  Millions$ 509.719  Millions
Travere Therapeutics Inc   0.59 $ 123.542  Millions$ 210.912  Millions
Clene Inc   0.58 $ 9.887  Millions$ 17.114  Millions
Zoetis Inc   0.57 $ 1,533.000  Millions$ 2,682.000  Millions
Organon and Co   0.55 $ 1,455.000  Millions$ 2,652.000  Millions
Medicus Pharma Ltd   0.52 $ 5.020  Millions$ 9.743  Millions
Bausch Health Companies Inc   0.51 $ 2,485.000  Millions$ 4,895.000  Millions
Neonc Technologies Holdings Inc   0.49 $ 10.966  Millions$ 22.241  Millions
Avenue Therapeutics Inc   0.47 $ 1.520  Millions$ 3.210  Millions
Royalty Pharma Plc  0.46 $ 544.857  Millions$ 1,179.003  Millions
Zymeworks Inc   0.45 $ 100.464  Millions$ 223.931  Millions
Organogenesis Holdings Inc   0.45 $ 21.326  Millions$ 47.649  Millions
Inmed Pharmaceuticals Inc  0.43 $ 1.140  Millions$ 2.673  Millions
Kiniksa Pharmaceuticals International Plc  0.43 $ 81.660  Millions$ 191.855  Millions
Syndax Pharmaceuticals Inc   0.40 $ 146.094  Millions$ 361.833  Millions
Vanda Pharmaceuticals Inc   0.40 $ 62.038  Millions$ 154.980  Millions
Ultragenyx Pharmaceutical Inc   0.39 $ 150.000  Millions$ 389.000  Millions
Biomarin Pharmaceutical Inc  0.38 $ 736.007  Millions$ 1,913.942  Millions
Earth Science Tech Inc   0.38 $ 1.009  Millions$ 2.639  Millions
Aurinia Pharmaceuticals Inc   0.36 $ 45.792  Millions$ 127.629  Millions
Merck and Co Inc   0.34 $ 9,650.000  Millions$ 28,801.000  Millions
Cytodyn inc   0.33 $ 16.359  Millions$ 49.700  Millions
Johnson and Johnson  0.31 $ 17,228.000  Millions$ 55,457.000  Millions
Evolus Inc   0.29 $ 41.700  Millions$ 142.378  Millions
Phibro Animal Health Corporation  0.28 $ 83.123  Millions$ 295.787  Millions
Viatris Inc   0.28 $ 1,859.100  Millions$ 6,636.500  Millions
Prestige Consumer Healthcare Inc   0.28 $ 46.515  Millions$ 168.503  Millions

Date modified: 2026-11-05T14:30:35+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.